How Consistent are Publicly Reported Cytotoxicity Data? Large‐Scale Statistical Analysis of the Concordance of Public Independent Cytotoxicity Measurements
暂无分享,去创建一个
[1] D. Banerjee,et al. Cytotoxicity and Cell Growth Assays , 2006 .
[2] I. Cree,et al. Comparison of MTT and ATP-based assays for the measurement of viable cell number. , 1995, Journal of bioluminescence and chemiluminescence.
[3] Jean-Pierre Gillet,et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance , 2011, Proceedings of the National Academy of Sciences.
[4] F. Balis,et al. Evolution of anticancer drug discovery and the role of cell-based screening. , 2002, Journal of the National Cancer Institute.
[5] J. Goodisman,et al. Cytotoxicity of Cu(II) and Zn(II) 2,2'-bipyridyl complexes: dependence of IC50 on recovery time. , 2010, Chemical research in toxicology.
[6] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[7] Jean-Pierre Gillet,et al. The clinical relevance of cancer cell lines. , 2013, Journal of the National Cancer Institute.
[8] J. Balzarini,et al. Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase. , 2011, European journal of medicinal chemistry.
[9] Mathew J Garnett,et al. The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response? , 2014, Current opinion in genetics & development.
[10] Karsten M. Borgwardt,et al. Prediction of human population responses to toxic compounds by a collaborative competition , 2015, Nature Biotechnology.
[11] A. Hubbard,et al. Toxicogenomic profiling of chemically exposed humans in risk assessment. , 2010, Mutation research.
[12] Mohammad Fallahi-Sichani,et al. Metrics other than potency reveal systematic variation in responses to cancer drugs. , 2013, Nature chemical biology.
[13] Ben van Ommen,et al. Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology , 2005, Expert review of proteomics.
[14] Pekka Tiikkainen,et al. Estimating Error Rates in Bioactivity Databases , 2013, J. Chem. Inf. Model..
[15] Verena M C Quent,et al. Discrepancies between metabolic activity and DNA content as tool to assess cell proliferation in cancer research , 2010, Journal of cellular and molecular medicine.
[16] Julio Saez-Rodriguez,et al. Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties , 2012, PloS one.
[17] C. Sander,et al. Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.
[18] M. Fellows,et al. Cytotoxicity in cultured mammalian cells is a function of the method used to estimate it. , 2007, Mutagenesis.
[19] Junying Yuan,et al. Cell death assays for drug discovery , 2011, Nature Reviews Drug Discovery.
[20] Brendan Borrell,et al. How accurate are cancer cell lines? , 2010, Nature.
[21] M. Hsiao,et al. Folate analogues. 26. Syntheses and antifolate activity of 10-substituted derivatives of 5,8-dideazafolic acid and of the poly-gamma-glutamyl metabolites of N10-propargyl-5,8-dideazafolic acid (PDDF). , 1986, Journal of medicinal chemistry.
[22] C. Lipinski. Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.
[23] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[24] A. Numata,et al. New class azaphilone produced by a marine fish-derived Chaetomium globosum. The stereochemistry and biological activities. , 2011, Bioorganic & medicinal chemistry.
[25] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[26] Suresh Kumar,et al. Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds. , 2012, European journal of medicinal chemistry.
[27] Isidro Cortes-Ciriano,et al. Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel , 2015, Bioinform..
[28] Scott P. Brown,et al. Healthy skepticism: assessing realistic model performance. , 2009, Drug discovery today.
[29] A. Joubert,et al. Limitations of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays , 2015, BMC Research Notes.
[30] Valerie Speirs,et al. Breast cancer cell lines: friend or foe? , 2003, Breast Cancer Research.
[31] Terry L Riss,et al. Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays. , 2004, Assay and drug development technologies.
[32] I. Wilson,et al. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. , 2000, European journal of biochemistry.
[33] D. Doolittle,et al. Evaluation of eight in vitro assays for assessing the cytotoxicity of cigarette smoke condensate. , 2002, Toxicology in vitro : an international journal published in association with BIBRA.
[34] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[35] Christoph Globisch,et al. Methoxylation of 3',4'-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells. , 2008, Bioorganic & medicinal chemistry.
[36] V. Tešević,et al. Isolation and biological evaluation of jatrophane diterpenoids from Euphorbia dendroides. , 2011, Journal of natural products.
[37] L. Kotra,et al. Design, Synthesis, Biological Evaluation, and Structure–Activity Relationships of Substituted Phenyl 4-(2-Oxoimidazolidin-1-yl)benzenesulfonates as New Tubulin Inhibitors Mimicking Combretastatin A-4 , 2011, Journal of medicinal chemistry.
[38] D. Emerson,et al. O-Phosphonatomethylcholine, its analogues, alkyl esters, and their biological activity. , 2001, Journal of medicinal chemistry.
[39] Christian Kramer,et al. QSARs, data and error in the modern age of drug discovery. , 2012, Current topics in medicinal chemistry.
[40] Sharon Patricia Mary Crouch,et al. High-throughput cytotoxicity screening: hit and miss , 2001 .
[41] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[42] P. Prusis,et al. Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospects , 2015 .
[43] Isidro Cortes-Ciriano,et al. Comparing the Influence of Simulated Experimental Errors on 12 Machine Learning Algorithms in Bioactivity Modeling Using 12 Diverse Data Sets , 2015, J. Chem. Inf. Model..
[44] L. Babiss,et al. Toxicogenomics in predictive toxicology in drug development. , 2004, Chemistry & biology.
[45] S. Bopp,et al. Comparison of four different colorimetric and fluorometric cytotoxicity assays in a zebrafish liver cell line , 2008, BMC pharmacology.
[46] Y. Tu,et al. Synthesis and cytotoxic activity of novel derivatives of 4'-demethylepipodophyllotoxin. , 2004, Bioorganic & medicinal chemistry letters.
[47] John A Timbrell,et al. In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. , 2006, Toxicology letters.
[48] Alexander Tropsha,et al. Curation of chemogenomics data. , 2015, Nature chemical biology.
[49] Jie Liu,et al. Synthesis and biological evaluation of conjugates of deoxypodophyllotoxin and 5-FU as inducer of caspase-3 and -7. , 2012, European journal of medicinal chemistry.
[50] J L Sebaugh,et al. Guidelines for accurate EC50/IC50 estimation , 2011, Pharmaceutical statistics.
[51] Philip L. Lorenzi,et al. Cancer: Discrepancies in drug sensitivity , 2013, Nature.
[52] J. Weinstein. Drug discovery: Cell lines battle cancer , 2012, Nature.
[53] Mark C. Wenlock,et al. How Experimental Errors Influence Drug Metabolism and Pharmacokinetic QSAR/QSPR Models , 2015, J. Chem. Inf. Model..
[54] T. Halazonetis,et al. Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.
[55] Sridhar Ramaswamy,et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..
[56] Joshua C. Gilbert,et al. An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules , 2013, Cell.
[57] D. Baccanari,et al. Methotrexate analogues. 30. Dihydrofolate reductase inhibition and in vitro tumor cell growth inhibition by N epsilon-(haloacetyl)-L-lysine and N delta-(haloacetyl)-L-ornithine analogues and an acivicin analogue of methotrexate. , 1987, Journal of medicinal chemistry.
[58] David A. Winkler,et al. Beware of R2: Simple, Unambiguous Assessment of the Prediction Accuracy of QSAR and QSPR Models , 2015, J. Chem. Inf. Model..
[59] A. Vulpetti,et al. Comparability of Mixed IC50 Data – A Statistical Analysis , 2013, PloS one.
[60] Benjamin Haibe-Kains,et al. Inconsistency in large pharmacogenomic studies , 2013, Nature.
[61] Kanyawim Kirtikara,et al. Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.
[62] A. Vulpetti,et al. The experimental uncertainty of heterogeneous public K(i) data. , 2012, Journal of medicinal chemistry.
[63] Andreas Zimmer,et al. A practical note on the use of cytotoxicity assays. , 2005, International journal of pharmaceutics.
[64] A. Meager,et al. Evaluation of assay designs for assays using microtitre plates: results of a study of in vitro bioassays and immunoassays for tumour necrosis factor (TNF). , 1995, Biologicals : journal of the International Association of Biological Standardization.